Boehringer Ingelheim and Lilly announce Trajenta®』s CARMELINA® cardiovascular outcome trial met its primary endpoint
The study included 6,979 adults with type 2 diabetes and high cardiovascular risk.1 The majority of patients also had kidney disease, an important risk factor for cardiovascular disease. The......